Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo

Drug Development: FDA's Priority Review Voucher Programs

  Premium   Download PDF Now (43 pages)
Report Type Reports and Testimonies
Report Date Jan. 31, 2020
Release Date Jan. 31, 2020
Report No. GAO-20-251
Summary:

Drugs that treat certain tropical diseases, rare pediatric diseases and illnesses related to public health emergencies are essential—but they may not be the most profitable to make.

When drug developers make these kinds of drugs, FDA can award them “priority review vouchers.” Drug developers can redeem a voucher to speed up FDA review of a future—potentially more profitable—drug. Vouchers can also be sold to other developers.

Some studies found that these vouchers had little or no effect on drug development, but all 7 drug developers we spoke to indicated that the vouchers were a factor in their decisions.

Prescription drugs

Prescription drugs

« Return to search Government Accountability Office reports